Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genmab has initiated a clinical trial titled A First-In-Human, Open-Label, Dose Escalation Trial to Evaluate the Safety and Antitumor Activity of GEN1057 in Subjects With Malignant Solid Tumors. The study aims to assess the safety and antitumor activity of the antibody GEN1057 in treating certain types of cancer, marking a significant step in cancer therapeutics.
The intervention being tested is GEN1057, administered as an intravenous infusion. This experimental drug is designed to target malignant solid tumors, with the goal of determining its safety and efficacy as a monotherapy.
The study is interventional, non-randomized, and follows a sequential intervention model without masking. Its primary purpose is treatment, focusing on evaluating different dose levels for safety and early efficacy signals.
The trial began on August 28, 2024, with an estimated primary completion date around mid-2025. The most recent update was submitted on July 7, 2025, indicating ongoing recruitment and progress.
This update could positively influence Genmab’s stock performance by boosting investor confidence in the company’s innovative cancer treatment pipeline. As the trial progresses, it may also impact the competitive landscape in oncology therapeutics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.